Leadership Overview
Novo Nordisk has 7 executives leading key functions including marketing, finance, operations, corporate affairs, strategic projects, and regional leadership.
Driven by a commitment to chronic disease management, Novo Nordisk advances global health through innovative biological medicines and sophisticated drug delivery systems for patients worldwide.
Driven by a commitment to chronic disease management, Novo Nordisk advances global health through innovative biological medicines and sophisticated drug delivery systems for patients worldwide.
Leadership Roles at Novo Nordisk
ViNay Nagaraja - Novo Nordisk Head of Finance & Operations (Affiliate Chief Financial Officer, Malaysia)
ViNay Nagaraja, the Novo Nordisk Head of Finance & Operations (Affiliate Chief Financial Officer, Malaysia) at Novo Nordisk, manages fiscal planning and operational infrastructure within the Southeast Asian market. Overseeing regional budget allocation, the Affiliate Chief Financial Officer ensures strict adherence to corporate financial governance and regulatory standards. This leadership role involves streamlining supply chain logistics to support the distribution of biological medicines for chronic conditions. By implementing robust financial reporting systems, ViNay Nagaraja directly impacts the company's regional profitability and resource efficiency. Furthermore, the Head of Finance & Operations collaborates with local stakeholders to expand access to essential treatments. Through meticulous risk management and capital investment strategies, the executive supports the broader organizational mission of improving health outcomes. Ultimately, Nagaraja secures financial stability and operational agility for the affiliate, fostering growth in a critical emerging market.
Aude Chemin - Senior Director, Finance Operations & Chief Financial Officer
Aude Chemin, the Senior Director, Finance Operations & Chief Financial Officer at Novo Nordisk, oversees global financial strategy and the integrity of fiscal operations. Directing capital allocation and investment planning, the Chief Financial Officer ensures that resources support the company's commitment to research and development for serious chronic diseases. This leadership role involves managing complex financial reporting structures to maintain transparency and compliance with international standards. By optimizing cost structures and driving financial discipline, Aude Chemin directly impacts the company's ability to fund large-scale production and innovation. Furthermore, the Senior Director collaborates with the Board to evaluate long-term growth opportunities and risk mitigation strategies. Through precise financial modeling and strategic oversight, the executive maintains the company's strong market position. Ultimately, Chemin secures the financial foundation necessary to expand access to life-changing therapies for patients living with diabetes and obesity.
Kes Kotani - President & Representative & Director, Novo Nordisk Pharma Ltd (Japan)
Kes Kotani, the President & Representative & Director, Novo Nordisk Pharma Ltd (Japan) at Novo Nordisk, leads all commercial and operational activities within the Japanese pharmaceutical market. Overseeing the introduction of advanced drug delivery systems, the President ensures that the company meets the specific needs of patients with chronic conditions in this highly regulated environment. This leadership role involves managing relationships with national health authorities and key medical institutions to ensure broad access to innovative therapies. By driving strategic growth and maintaining high standards of quality, Kes Kotani directly impacts the company's success in the Asia-Pacific region. Furthermore, the Director fosters a culture of innovation and excellence within the local team. Through visionary leadership and deep market expertise, the executive secures a competitive advantage. Ultimately, Kotani ensures that the Japanese affiliate remains a cornerstone of the company's global strategy for treating serious chronic diseases.
Yongbin Jiang - Senior Project Manager, To The & Chief Marketing Officer
Yongbin Jiang, the Senior Project Manager, To The & Chief Marketing Officer at Novo Nordisk, directs global brand positioning and commercial strategy for diabetes and obesity portfolios. Overseeing complex product launches, the Chief Marketing Officer ensures alignment between scientific research and market demand. This leadership role involves architecting digital engagement platforms to improve patient access to life-changing therapies. By optimizing marketing spend and channel efficiency, Yongbin Jiang directly impacts the company's market share in competitive pharmaceutical sectors. Furthermore, the Chief Marketing Officer coordinates with regional teams to tailor messaging for diverse patient populations. Through rigorous data analysis and consumer insights, the executive drives sustainable growth across international markets. Ultimately, Jiang secures long-term brand equity by maintaining high standards of operational excellence and patient-centric communication strategies within the global pharmaceutical landscape.
Pablo Gebauer - Chief of Staff & Associate Director, Corporate Affairs LATAM (Excluding Mexico & Brazil)
Pablo Gebauer, the Chief of Staff & Associate Director, Corporate Affairs LATAM (Excluding Mexico & Brazil) at Novo Nordisk, coordinates strategic initiatives and public policy engagement across the Latin American region. Overseeing stakeholder relations, the Associate Director ensures consistent communication of the company's mission regarding rare blood and endocrine disorders. This leadership role involves navigating complex regulatory environments to facilitate the introduction of innovative drug delivery systems. By fostering partnerships with healthcare providers and government entities, Pablo Gebauer directly impacts the company's reputation and market access. Furthermore, the Chief of Staff aligns regional corporate affairs with global sustainability goals. Through proactive advocacy and strategic planning, the executive strengthens the company's presence in diverse markets. Ultimately, Gebauer secures a favorable operating environment by championing patient-centric policies and maintaining transparent dialogue with key regional influencers throughout the LATAM territory.
Lilian Obat - Strategic Projects Chief of Staff
Lilian Obat, the Strategic Projects Chief of Staff at Novo Nordisk, executes high-priority initiatives designed to enhance organizational efficiency and cross-functional collaboration. Overseeing the implementation of advanced manufacturing capabilities, the Chief of Staff ensures that internal processes support the rapid development of biological medicines. This leadership role involves bridging communication gaps between research departments and commercial teams to accelerate project timelines. By optimizing internal workflows, Lilian Obat directly impacts the company's ability to scale production for chronic disease treatments. Furthermore, the executive monitors key performance indicators to ensure alignment with long-term corporate objectives. Through rigorous project management and strategic oversight, the Chief of Staff drives operational excellence across the global enterprise. Ultimately, Obat secures the successful delivery of critical business transformations, ensuring that the company remains at the forefront of pharmaceutical innovation and patient care delivery.
Miguel Galeti - Chief of Staff (Brazil)
Miguel Galeti, the Chief of Staff (Brazil) at Novo Nordisk, manages executive operations and strategic alignment within the Brazilian market. Overseeing the execution of local business plans, the Chief of Staff ensures that the company's focus on diabetes and obesity treatments remains a priority for regional healthcare systems. This leadership role involves coordinating between local leadership and global headquarters to streamline decision-making processes. By facilitating cross-departmental collaboration, Miguel Galeti directly impacts the company's operational efficiency and market penetration in South America. Furthermore, the executive monitors local market trends to adapt strategies for changing patient needs. Through proactive management of internal resources and external partnerships, the Chief of Staff supports the company's mission of improving health outcomes. Ultimately, Galeti secures the successful implementation of corporate initiatives, ensuring that the Brazilian affiliate contributes effectively to the global pharmaceutical goals of the organization.
Explore Leadership Teams in Manufacturing
Headquartered in Woodbury, Minnesota, Kindeva Drug Delivery is a leading global contract development and manufacturing organization (CDMO) in the pharmaceutical industry. Kindeva provides unique technologies and quality services to its customers, ranging from formulation and product development to commercial manufacturing. Kindeva focuses on complex drug programs, and its current offering spans inhalation drug delivery, transdermal drug delivery, microstructured transdermal systems (microsystems), and connected drug delivery.
Company Leadership DS

BS
Sumitomo Pharma seeks to continuously create innovative pharmaceutical products by pursuing R&D activities focused on Psychiatry & Neurology, Oncology, and Regenerative Medicine & Cell Therapy, all the while incorporating cutting-edge technologies. We also seek to contribute to Global Health through our work in the area of Infectious Disease, and furthermore, through our Frontier Business, we are pursuing R&D and commercialization of new healthcare solutions other than pharmaceuticals for addressing social issues which cannot be solved by pharmaceuticals alone.
Company Leadership SK
JH
TS
AS
Divis Laboratories Limited is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) based in Hyderabad, India, recognized as one of the top three API manufacturers globally. The company specializes in Generic APIs, Custom Synthesis, and Nutraceuticals, serving over 100 countries and providing high-quality products to major pharmaceutical companies. With a commitment to quality and sustainability, Divis operates extensive manufacturing facilities and R&D centers, employing over 2,500 analysts to ensure compliance with stringent global standards. Their diverse portfolio includes a wide range of carotenoids and vitamins, catering to the nutritional, pharmaceutical, and food industries.
Company Leadership

KL
MJ
Founded in 2001 and headquartered in Moscow, Russia, R-Pharm is a pharmaceutical company. The company is involved in R&D, manufacturing (finished dosage forms, biotech and chemical APIs), marketing, sales and distribution of innovative pharmaceutical products in hospital/specialty care therapeutic areas.
Company Leadership OB
AS
BO